
Sandoz takes Amgen to court again, challenging its patents on decades-old Enbrel
Originally approved by the FDA in 1998, Amgen’s Enbrel is still sailing along without facing biosimilar competition in the United States. And unless a court rules otherwise, the Southern California company will retain its patent protection on the …